Cardiff Oncology, Inc. (CRDF)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Royalty revenues | 121 | 109 | 165 | 163 |
| Selling, general and administrative | 3,318 | 4,014 | 3,126 | 3,215 |
| Research and development | 11,580 | 10,477 | 9,640 | 9,493 |
| Total operating expenses | 14,898 | 14,491 | 12,766 | 12,708 |
| Loss from operations | -14,777 | -14,382 | -12,601 | -12,545 |
| Other income (expense), net | -1 | 7 | 5 | -38 |
| Interest income, net | 835 | 941 | 741 | 805 |
| Total other income (expense), net | 834 | 948 | 746 | 767 |
| Net loss | -13,943 | -13,434 | -11,855 | -11,778 |
| Preferred stock dividend payable on series a convertible preferred stock | 6 | 6 | 6 | 6 |
| Net loss attributable to common stockholders | -13,949 | -13,440 | -11,861 | -11,784 |
| Earnings per share, basic | -0.21 | -0.2 | -0.25 | -0.26 |
| Earnings per share, diluted | -0.21 | -0.2 | -0.25 | -0.26 |
| Weighted average number of shares outstanding, basic | 66,526,000 | 66,524,000 | 46,865,000 | 44,825,000 |
| Weighted average number of shares outstanding, diluted | 66,526,000 | 66,524,000 | 46,865,000 | 44,825,000 |